<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Progestogen-only pill | Management | Contraception - progestogen-only methods | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the use of the progestogen-only pill (POP), including the available products; when to start it; the efficacy; how to manage common problems (such as missed pills); the advantages, disadvantages, risks, possible adverse effects and key drug interactions; and follow up requirements for this method of contraception."/><meta data-react-helmet="true" property="og:description" content="Covers the use of the progestogen-only pill (POP), including the available products; when to start it; the efficacy; how to manage common problems (such as missed pills); the advantages, disadvantages, risks, possible adverse effects and key drug interactions; and follow up requirements for this method of contraception."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/contraception-progestogen-only-methods/management/progestogen-only-pill/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Progestogen-only pill | Management | Contraception - progestogen-only methods | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/contraception-progestogen-only-methods/management/progestogen-only-pill/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Contraception - progestogen-only methods</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Progestogen-only pill</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/contraception-progestogen-only-methods/","name":"Contraception - progestogen-only methods"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/contraception-progestogen-only-methods/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Progestogen-only pill"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Contraception - progestogen-only methods: </span><span>Scenario: Progestogen-only pill</span></h1><p class="page-header__lead"><span>Last revised in November 2019</span></p></div><p class="visually-hidden">Covers the use of the progestogen-only pill (POP), including the available products; when to start it; the efficacy; how to manage common problems (such as missed pills); the advantages, disadvantages, risks, possible adverse effects and key drug interactions; and follow up requirements for this method of contraception.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Contraception - progestogen-only methods chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Progestogen-only pill"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Progestogen-only pill</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Progestogen-only implant"><a aria-current="false" href="../progestogen-only-implant/index.html"><span class="stacked-nav__content-wrapper">Scenario: Progestogen-only implant</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Progestogen-only injectables"><a aria-current="false" href="../progestogen-only-injectables/index.html"><span class="stacked-nav__content-wrapper">Scenario: Progestogen-only injectables</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#starting-a-progestogen-only-pill">Starting a progestogen-only pill</a><ol aria-label="Sections within Starting a progestogen-only pill" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#assessment">Assessment</a></li><li class=""><a href="index.html#types-of-progestogen-only-pill">Types of progestogen-only pill</a></li><li class=""><a href="index.html#first-line-progestogen-only-pill">First line progestogen-only pill</a></li><li class=""><a href="index.html#quantity-of-progestogen-only-pill">Quantity of progestogen-only pill</a></li><li class=""><a href="index.html#when-to-start">When to start</a></li><li class=""><a href="index.html#when-to-start-amenorrhoea">When to start - Amenorrhoea</a></li><li class=""><a href="index.html#when-to-start-excluding-pregnancy">When to start - excluding pregnancy</a></li><li class=""><a href="index.html#mechanism-of-action">Mechanism of action</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-aa4">Basis for recommendation</a></li></ol></li><li><a href="index.html#information-advice">Information and advice</a><ol aria-label="Sections within Information and advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#missed-pill">Missed pill</a></li><li class=""><a href="index.html#pregnancy">Pregnancy</a></li><li class=""><a href="index.html#vomiting-or-diarrhoea">Vomiting or diarrhoea</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-2ae">Basis for recommendation</a></li></ol></li><li><a href="index.html#advantages-disadvantages">Advantages and disadvantages</a><ol aria-label="Sections within Advantages and disadvantages" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-352">Basis for recommendation</a></li></ol></li><li><a href="index.html#risks-adverse-effects">Risks and adverse effects</a><ol aria-label="Sections within Risks and adverse effects" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#unscheduled-bleeding">Unscheduled bleeding</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-ada">Basis for recommendation</a></li></ol></li><li><a href="index.html#efficacy">Efficacy</a><ol aria-label="Sections within Efficacy" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-864">Basis for recommendation</a></li></ol></li><li><a href="index.html#drug-interactions">Drug interactions</a><ol aria-label="Sections within Drug interactions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-4f3">Basis for recommendation</a></li></ol></li><li><a href="index.html#follow-up">Follow up</a><ol aria-label="Sections within Follow up" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#duration-of-use">Duration of use</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-0e7">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="progestogen-only-pill" class="ChapterBody-module--wrapper--2HCfk "><h2 id="progestogen-only-pill" class="visually-hidden">Scenario: Progestogen-only pill</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c2a82b13-3dd7-4573-b603-7586df77e9c8 --><!-- begin field fcb0dc9e-15b9-4382-96ce-acbc015798ca --><p>From age 13 years to 60 years (Female).</p><!-- end field fcb0dc9e-15b9-4382-96ce-acbc015798ca --><!-- end item c2a82b13-3dd7-4573-b603-7586df77e9c8 --></div><section aria-labelledby="starting-a-progestogen-only-pill" class="ChapterBody-module--wrapper--2HCfk "><h3 id="starting-a-progestogen-only-pill">Starting a progestogen-only pill</h3><section aria-labelledby="assessment" class="ChapterBody-module--wrapper--2HCfk "><h4 id="assessment">How should I assess a woman who is considering starting the progestogen-only pill?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item baf41e85-f338-47e8-b695-41749edf9f1f --><!-- begin field 9df3e7ed-f586-402f-9b88-9387824475c7 --><ul><li>For information on assessing a woman considering starting a progestogen-only pill, see the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a>.</li></ul><!-- end field 9df3e7ed-f586-402f-9b88-9387824475c7 --><!-- end item baf41e85-f338-47e8-b695-41749edf9f1f --></div></section><section aria-labelledby="types-of-progestogen-only-pill" class="ChapterBody-module--wrapper--2HCfk "><h4 id="types-of-progestogen-only-pill">What types of progestogen-only pills (POPs) are available?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 020405fe-ea71-4a17-b477-a7a700eb044c --><!-- begin field e000d989-32cf-498c-8523-a7a700eb06f3 --><ul><li>The progestogen-only pills licensed in the UK are:<ul><li>Norgeston® (levonorgestrel 30 micrograms).</li><li>Noriday®, Micronor® (norethisterone 350 micrograms).</li><li>Cerazette®, Cerelle®, Feanolla®, Aizea® (desogestrel 75 micrograms).</li><li>A generic desogestrel 75 micrograms.</li></ul></li><li>Progestogen-only pills should be taken daily at the same time each day for 28 days, with no pill-free interval.</li></ul><!-- end field e000d989-32cf-498c-8523-a7a700eb06f3 --><!-- end item 020405fe-ea71-4a17-b477-a7a700eb044c --></div></section><section aria-labelledby="first-line-progestogen-only-pill" class="ChapterBody-module--wrapper--2HCfk "><h4 id="first-line-progestogen-only-pill">Which progestogen-only pill should I offer first-line?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5ae535a4-f070-4cb3-92bb-a6cd01057ecb --><!-- begin field dcbd8109-297e-41dc-9d54-a6cd0105802e --><ul><li>Any licensed progestogen-only pill (POP) may be used first-line.</li><li>However, possible adverse effects and/or rules about missed pills differ between products and this may affect their acceptability. For example:<ul><li>Irregular bleeding (particularly in the first few months) may be more of a problem with the desogestrel-only pill than with other POPs.</li><li>If the woman is unable to consistently take her pill at the same time every day, or within 3 hours of the usual pill time, consider prescribing desogestrel, which should be taken at the same time every day or within 12 hours of the usual pill time.</li></ul></li></ul><!-- end field dcbd8109-297e-41dc-9d54-a6cd0105802e --><!-- end item 5ae535a4-f070-4cb3-92bb-a6cd01057ecb --></div></section><section aria-labelledby="quantity-of-progestogen-only-pill" class="ChapterBody-module--wrapper--2HCfk "><h4 id="quantity-of-progestogen-only-pill">What quantity of POP should I prescribe?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9f9fad8d-62f7-4f25-969d-a6cd010c02a0 --><!-- begin field d7a1d748-0ca7-4749-8eb4-a6cd010c041a --><ul><li>Prescribe 3–6 months' supply of progestogen-only pills at the first visit and up to 12 months' supply at follow up visits. </li></ul><!-- end field d7a1d748-0ca7-4749-8eb4-a6cd010c041a --><!-- end item 9f9fad8d-62f7-4f25-969d-a6cd010c02a0 --></div></section><section aria-labelledby="when-to-start" class="ChapterBody-module--wrapper--2HCfk "><h4 id="when-to-start">When should a woman start a progestogen-only pill?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item dfba7f9b-0ddf-4d33-b36d-fdcf535a3f4b --><!-- begin field eee63038-d9f0-45c0-822d-b497dfbd9161 --><p>Specific advice for women who are amenorrhoeic, postpartum and breastfeeding, postpartum and not breastfeeding, post-termination of pregnancy, or post-miscarriage is summarized in the section on <a class="topic-reference internal-reference" href="index.html#when-to-start-amenorrhoea">Amenorrhoea, postpartum, termination of pregnancy, or miscarriage</a>. </p><ul><li><strong>If the woman is <em>not </em>currently using a regular method of contraception or using a barrier method (such as condoms):</strong><ul><li>Start the progestogen-only pill (POP) on days 1 to 5 of the menstrual cycle.<ul><li>No additional contraception is required.</li></ul></li><li>If the POP is started at any other time in the menstrual cycle, and it is reasonably certain that the women is not pregnant and there has been no risk of conception (off-label use):<ul><li>Advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for 48 hours after starting the pill.</li></ul></li><li>If pregnancy cannot be excluded and the women wishes to start a hormonal method of contraception without delay:<ul><li>Assess the need for emergency contraception (EC) and prescribe if necessary. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-emergency/index.html">Contraception - emergency</a>.</li><li>Prescribe the POP.</li><li>Advise the woman to have a pregnancy test no sooner 3 weeks after the last episode of unprotected sexual intercourse (UPSI).</li></ul></li></ul></li><li><strong>If the woman is starting the POP after oral EC:</strong><ul><li>For levonorgestrel, start the POP immediately, and advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for the first 2 days.</li><li>For ulipristal acetate, start the POP 5 days after taking oral ulipristal acetate, and advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) during this time and for the first 2 days of taking the POP.</li><li>Advise the woman to have a pregnancy test no sooner than 3 weeks after the last episode of UPSI.</li></ul></li><li><strong>If the woman is changing from another POP:</strong><ul><li>Start the POP at any time</li><li>No additional contraception is required.</li></ul></li><li><strong>If the woman is changing from a combined hormonal contraceptive (CHC): </strong><ul><li>Start the POP on days 1 to 7 of the hormone-free interval (day 1 is the optimal time to switch).<ul><li>No additional contraception is required.</li></ul></li><li>If the POP is started on week 1 of normal CHC use:<ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 48 hours after starting the POP.</li><li>If UPSI has occurred in the hormone-free interval, or week 1, continue the CHC for 7 consecutive days before switching.</li><li>If CHC cannot be continued, switch to the POP immediately. Consider the need for EC and a pregnancy test if pregnancy cannot be excluded. </li></ul></li><li>If the POP is started on weeks 2–3 of CHC use:<ul><li>No additional precautions are required if the method has been used correctly for the previous 7 days. </li></ul></li></ul></li><li><strong>If the woman is changing from an injectable progestogen-only contraceptive:</strong><ul><li>Start the POP up to 14 weeks after the last injection.<ul><li>No additional contraception is required.</li></ul></li><li>If the POP is started more than 14 weeks after the last injection. <ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 48 hours after starting the POP.</li><li>Consider the need for EC, and a pregnancy test if pregnancy cannot be excluded.</li></ul></li></ul></li><li><strong>If the woman is changing from the progestogen-only implant:</strong><ul><li>Start the POP up to 3 years after insertion of the implant. <ul><li>No additional contraception is required.</li></ul></li><li>If the POP is started more than 3 years after insertion:<ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 48 hours after starting the POP.</li><li>Consider the need for EC, and a pregnancy test if pregnancy cannot be excluded.</li></ul></li></ul></li><li><strong>If the woman is changing from a copper intrauterine device (Cu-IUD)</strong><ul><li>Start the POP at least 2 days before removal of the Cu-IUD.<ul><li> No additional contraception is required.</li></ul></li><li>If the POP is started on the day of the IUD removal, provided that there has been no UPSI in the preceding 7 days. <ul><li>Advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for 48 hours after starting the POP.</li><li>Consider the need for EC, and a pregnancy test if pregnancy cannot be excluded.</li></ul></li></ul></li><li><strong>If the woman is changing from a levonorgestrel intrauterine system (LNG-IUS) </strong><ul><li>Start the POP at least 2 days before removal of the LNG-IUS.<ul><li>No additional contraception is required.</li></ul></li><li>If the POP is started on the day of removal of the LNG-IUS.<ul><li>Advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for 48 hours after starting the POP.</li><li>Consider the need for EC, and a pregnancy test if pregnancy cannot be excluded.</li></ul></li></ul></li></ul><!-- end field eee63038-d9f0-45c0-822d-b497dfbd9161 --><!-- end item dfba7f9b-0ddf-4d33-b36d-fdcf535a3f4b --></div></section><section aria-labelledby="when-to-start-amenorrhoea" class="ChapterBody-module--wrapper--2HCfk "><h4 id="when-to-start-amenorrhoea">Amenorrhoea, postpartum, termination of pregnancy, or miscarriage</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6c30adc7-13aa-4553-9e96-a6cd010d9041 --><!-- begin field 6059c1bb-5b54-470a-bb47-a6cd010d9147 --><ul><li><strong>If the woman is amenorrhoeic:</strong><ul><li>Start the progestogen-only pill (POP) at any time, provided it is reasonably certain that the woman is not pregnant.<ul><li>Additional contraception is required for 48 hours.</li><li>Consider the need for emergency contraception, and advise the woman to take a pregnancy test no sooner than 3 weeks after the last episode of unprotected sexual intercourse (UPSI). </li></ul></li></ul></li><li><strong>If the woman is postpartum (whether breastfeeding or not):</strong><ul><li>Start the POP at any time.<ul><li>If started before day 21 postpartum, no additional contraception is required.</li></ul></li><li>If started after day 21 postpartum, advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 48 hours after starting the POP, unless she is using the lactational amenorrhoea method (LAM) of contraception. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-natural-family-planning/index.html">Contraception - natural family planning</a>, for more information on the LAM.<ul><li>Consider the need for emergency contraception (EC), and advise the woman to take a pregnancy test no sooner than 3 weeks after the last episode of UPSI. </li></ul></li></ul></li><li><strong>If the woman has had a miscarriage or termination of pregnancy: </strong><ul><li>If gestation is less than 24 weeks, ideally, start the POP on the day of a miscarriage, surgical termination, or first part of a medical termination.<ul><li>If the POP is started within 5 days of miscarriage or termination, no additional contraception is required.</li></ul></li><li>If the POP is started 5 days or more after miscarriage or termination, advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 48 hours.<ul><li>Consider the need for EC, and advise the woman to take a pregnancy test no sooner than 3 weeks after the last episode of UPSI. </li></ul></li><li>If gestation is 24 weeks or more, treat as for a woman who is postpartum.</li></ul></li></ul><!-- end field 6059c1bb-5b54-470a-bb47-a6cd010d9147 --><!-- end item 6c30adc7-13aa-4553-9e96-a6cd010d9041 --></div></section><section aria-labelledby="when-to-start-excluding-pregnancy" class="ChapterBody-module--wrapper--2HCfk "><h4 id="when-to-start-excluding-pregnancy">Excluding pregnancy</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9be7b0be-fdb6-4cee-960f-a6cd010da460 --><!-- begin field 39eae606-2a5d-46fd-912d-a6cd010da578 --><ul><li>Health professionals can be ‘reasonably certain’ that a woman is not pregnant if there are no signs or symptoms of pregnancy and one or more of the following criteria are met. The woman:<ul><li>Has not had sexual intercourse since the last normal menses.</li><li>Has used a reliable method of contraception correctly and consistently.</li><li>Is within the first 7 days of the onset of a normal menstrual period.</li><li>Is within 4 weeks postpartum for non-breastfeeding women.</li><li>Is within the first 7 days post-termination of pregnancy, or miscarriage.</li><li>Is fully or nearly fully breastfeeding, amenorrhoeic, and less than 6 months postpartum.</li><li>A pregnancy test is performed no sooner than 3 weeks since the last episode of unprotected sexual intercourse (UPSI) and is negative.</li></ul></li></ul><!-- end field 39eae606-2a5d-46fd-912d-a6cd010da578 --><!-- end item 9be7b0be-fdb6-4cee-960f-a6cd010da460 --></div></section><section aria-labelledby="mechanism-of-action" class="ChapterBody-module--wrapper--2HCfk "><h4 id="mechanism-of-action">What is the mechanism of action of progestogen-only pills (POPs)?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 19d37df4-6fd7-41e8-83dc-ed6f57e1d51b --><!-- begin field 5d520e2a-95c2-4958-9aee-d1ac95ec876a --><ul><li>Progestogen-only pills (POPs) have five independent modes of action:</li><ul><li>Suppression of ovulation — this occurs in varying degrees (97% in women taking desogestrel and about 60% in woman taking levonorgestrel [Norgeston®]).<br></li><li>Suppression of mid-cycle peaks of luteinizing hormone and follicle-stimulating hormone.<br></li><li>Production of 'hostile, blocked' mucus, resulting in poor sperm penetration.<br></li><li>Reduction in the number and size of endometrial glands and inhibition of progesterone receptor synthesis in the endometrium, preventing implantation.<br></li><li>Reduction in the activity of cilia in the Fallopian tube.<br></li><li>POPs prevent conception (even when ovulation is not suppressed) through various combinations of these mechanisms, with great inter-individual and intra-individual variation.</li></ul></ul><!-- end field 5d520e2a-95c2-4958-9aee-d1ac95ec876a --><!-- end item 19d37df4-6fd7-41e8-83dc-ed6f57e1d51b --></div></section><section aria-labelledby="basis-for-recommendation-aa4" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-aa4">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item aa4db5b9-1ae7-4b59-b222-a6cd0104d190 --><!-- begin field c21c69a7-6216-4632-95e6-a6cd0104d2c2 --><h5>Types of progestogen only pill</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only pills</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015a</a>] and the British National Formulary [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 71, 2016</a>].</li></ul><h5>Quantity of progestogen-only pill (POP) to prescribe</h5><ul><li>The FRSH recommends prescribing up to 12 months' supply at the first visit, however CKS recommends initially prescribing 3–6 months' supply until the first follow-up visit, to ensure the POP is suitable before prescribing a larger quantity.</li></ul><h5>When to start</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only pills</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015a</a>], <em>UK Medical Eligibility Criteria for contraceptive use</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>], <em>Quick starting contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2010a</a>], <em>Contraception after pregnancy </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2017b</a>], and a statement from the FSRH clinical effectiveness unit [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015b</a>].</li></ul><h5>Mechanism of action</h5><ul><li><p>This information is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline, <em>Progestogen-only pills</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015a</a>].</p></li></ul><!-- end field c21c69a7-6216-4632-95e6-a6cd0104d2c2 --><!-- end item aa4db5b9-1ae7-4b59-b222-a6cd0104d190 --></div></section></section><section aria-labelledby="information-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="information-advice">What information and advice should I give a woman who is considering using a progestogen-only pill (POP)?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 91f1ac12-401d-4d3e-ae2c-19a74d5d3f29 --><!-- begin field d2d8de91-d75e-46ac-b357-f3b5ebeb1619 --><ul><li><strong>Discuss:</strong><ul><li>The <a class="topic-reference internal-reference" href="index.html#mechanism-of-action">mechanism of action</a> of the progestogen-only pill (POP).</li><li>The <a class="topic-reference internal-reference" href="index.html#advantages-disadvantages">advantages and disadvantages</a> of the POP.</li><li>The contraceptive <a class="topic-reference internal-reference" href="index.html#efficacy">efficacy</a> of the POP.</li><li>What happens when the POP is stopped — advise the woman that normal fertility returns as soon as the POP is stopped.</li></ul></li><li><strong>Give advice on:</strong><ul><li>The importance of taking the pill regularly at a time of day that will aid adherence.</li><li><a class="topic-reference internal-reference" href="index.html#missed-pill">Missed pills</a>.</li><li><a class="topic-reference internal-reference" href="index.html#vomiting-or-diarrhoea">Vomiting or diarrhoea</a> after taking the POP.</li><li>Possible <a class="topic-reference internal-reference" href="index.html#risks-adverse-effects">adverse effects</a> (such as <a class="topic-reference internal-reference" href="index.html#risks-adverse-effects">unscheduled bleeding</a>) of the POP.</li><li>The possibility of <a class="topic-reference internal-reference" href="index.html#drug-interactions">drug interactions</a>.<ul><li>Advise the woman to check with a healthcare professional before starting any new drug treatment (including herbal remedies).</li></ul></li></ul></li><li><strong>Also:</strong><ul><li>Provide written information on the POP. The <a href="http://www.fpa.org.uk/" data-hyperlink-id="17df99a8-dd81-4c3f-b266-a931009d3260">Family Planning Association</a> provides a useful <a href="http://www.fpa.org.uk/sites/default/files/progestogen-only-pill-your-guide.pdf" data-hyperlink-id="a3db11c6-bd8e-4578-a970-a931009d3396">leaflet</a> with information for women using the POP. </li><li>Offer verbal and/or written advice on long-acting reversible contraception (copper intrauterine device, levonorgestrel intrauterine system, progestogen-only injectables, progestogen-only implant, and the combined vaginal ring). See the CKS topics on <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a> and <a class="topic-reference external-reference" href="../../../contraception-combined-hormonal-methods/index.html">Contraception - combined hormonal methods</a> for more information on these methods of contraception.</li></ul></li></ul><!-- end field d2d8de91-d75e-46ac-b357-f3b5ebeb1619 --><!-- end item 91f1ac12-401d-4d3e-ae2c-19a74d5d3f29 --></div><section aria-labelledby="missed-pill" class="ChapterBody-module--wrapper--2HCfk "><h4 id="missed-pill">What missed pill advice should I give?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 06215d3a-2c4c-4ec5-8504-a7a700e992d6 --><!-- begin field 26204e36-9c2f-4bc6-bb38-a7a700e99516 --><ul><li>Check which progestogen-only pill (POP) the woman is taking and the time since the last pill was taken.<ul><li>For the desogestrel pill — a pill is missed if she is more than 12 hours late (that is more than 36 hours since taking the last pill).</li><li>For all other progestogen-only pills — a pill is missed if she is more than 2 hours late (that is more than 26 hours since taking the last pill).</li></ul></li><li>If the woman has missed any POP, she should:<ul><li>Take a pill as soon as possible.</li><li>Take the next pill at the normal time. This may mean taking two pills in 24 hours (the missed pill and the next one at the usual time).</li><li>Use a barrier method of contraception (such as condoms) for the next 48 hours, unless she is less than 6 months postpartum, fully breastfeeding, and amenorrhoeic.</li></ul></li><li>Consider prescribing emergency contraception if unprotected sexual intercourse has taken place after the missed pill and within 48 hours of restarting the POP. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-emergency/index.html">Contraception - emergency</a>.</li></ul><!-- end field 26204e36-9c2f-4bc6-bb38-a7a700e99516 --><!-- end item 06215d3a-2c4c-4ec5-8504-a7a700e992d6 --></div></section><section aria-labelledby="pregnancy" class="ChapterBody-module--wrapper--2HCfk "><h4 id="pregnancy">How should I manage a woman who becomes pregnant whilst using the progestogen-only pill?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 82f67087-bf3e-47e1-8df2-f36e89945705 --><!-- begin field 8fabd022-be6c-418f-ae9c-183ee407b034 --><ul><li>If a woman is found to be pregnant whilst using the progestogen-only pill (POP) and she wishes to continue with the pregnancy:<ul><li>Advise her to stop taking the POP.</li><li>Inform her that there is no evidence of harm to the baby or the mother if pregnancy occurs while using the POP.</li><li>Be alert to the possibility of an ectopic pregnancy. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../ectopic-pregnancy/index.html">Ectopic pregnancy</a>.</li></ul></li></ul><!-- end field 8fabd022-be6c-418f-ae9c-183ee407b034 --><!-- end item 82f67087-bf3e-47e1-8df2-f36e89945705 --></div></section><section aria-labelledby="vomiting-or-diarrhoea" class="ChapterBody-module--wrapper--2HCfk "><h4 id="vomiting-or-diarrhoea">What advice should I give a woman taking progestogen-only pills about vomiting or diarrhoea?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9453c37c-491d-4bb1-8d39-9bb84ea8cd9b --><!-- begin field 069d28a5-6b0b-4785-b651-102f2e2fec65 --><ul><li>If a woman vomits within 2 hours of pill taking, another pill should be taken as soon as possible. If the subsequent pill is missed, she should be given the instructions for <a class="topic-reference internal-reference" href="index.html#missed-pill">missed pills</a>.</li><li>If vomiting or diarrhoea persists for more than 24 hours, advise her to:<ul><li>Follow the instructions for missed pills, counting each day of vomiting and/or diarrhoea as a missed pill.</li><li>Avoid sexual intercourse or use a barrier method of contraception (such as condoms) during the illness and for 48 hours afterwards.</li></ul></li></ul><!-- end field 069d28a5-6b0b-4785-b651-102f2e2fec65 --><!-- end item 9453c37c-491d-4bb1-8d39-9bb84ea8cd9b --></div></section><section aria-labelledby="basis-for-recommendation-2ae" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-2ae">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2ae6cce9-3085-42fb-8ad6-a6cd011019f9 --><!-- begin field 17ef7c03-7b77-44e0-83ea-a6cd01101b53 --><h5>Information and advice</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline, <em>Progestogen-only pills</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015a</a>].</li></ul><h5>Missed pill</h5><ul><li><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only pills</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015a</a>].</p></li></ul><h5>Pregnancy</h5><ul><li><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only pills</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015a</a>], and the manufacturer's Summary of Product Characteristics [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2015a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016a</a>].</p></li></ul><h5>Vomiting or diarrhoea</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Drug interactions with hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2017a</a>].</li></ul><!-- end field 17ef7c03-7b77-44e0-83ea-a6cd01101b53 --><!-- end item 2ae6cce9-3085-42fb-8ad6-a6cd011019f9 --></div></section></section><section aria-labelledby="advantages-disadvantages" class="ChapterBody-module--wrapper--2HCfk "><h3 id="advantages-disadvantages">What are the advantages and disadvantages of progestogen-only pills (POPs)?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0fb0b440-ac35-4595-a708-4db55a93c77d --><!-- begin field 391ecd90-62b0-4f93-a4b1-ddc3329cb954 --><div><strong>Advantages</strong></div><ul><li>The progestogen-only pill (POP) is very effective when taken correctly and is more <a class="topic-reference internal-reference" href="index.html#efficacy">effective</a> than barrier methods of contraception. </li><li>Sex need not be interrupted to use the POP.</li><li>It can be used by women for whom the combined oral contraceptive is not suitable.</li><li>It may reduce the risk of endometrial cancer.</li><li>Desogestrel may be beneficial in managing dysmenorrhoea.</li><li>Normal fertility returns when the POP is stopped.</li></ul><h4>Disadvantages</h4><div><ul><li>Pills must be taken at the same time each day, or within 3 hours, except for the desogestrel-only pill, which must be taken within 12 hours to be effective.</li><li><a class="topic-reference internal-reference" href="index.html#risks-adverse-effects">Adverse effects</a> (such as unscheduled bleeding and breast tenderness) may be experienced by some women when they first start a POP, however these are transient. </li><li>The POP does not protect against sexually transmitted infections (STIs). People at risk of STIs should be advised to also use a barrier method of contraception (such as condoms). For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-barrier-methods-spermicides/index.html">Contraception - barrier methods and spermicides</a>.</li></ul></div><!-- end field 391ecd90-62b0-4f93-a4b1-ddc3329cb954 --><!-- end item 0fb0b440-ac35-4595-a708-4db55a93c77d --></div><section aria-labelledby="basis-for-recommendation-352" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-352">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3523178f-4b00-4b13-b9f1-550ea999e891 --><!-- begin field 57d48f8c-7645-4a69-a4e9-55eb7f1ff596 --><p>This information is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline, <em>Progestogen-only pills</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015a</a>] and the manufacturer's Summary of Product Characteristics [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2015a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016a</a>].</p><!-- end field 57d48f8c-7645-4a69-a4e9-55eb7f1ff596 --><!-- end item 3523178f-4b00-4b13-b9f1-550ea999e891 --></div></section></section><section aria-labelledby="risks-adverse-effects" class="ChapterBody-module--wrapper--2HCfk "><h3 id="risks-adverse-effects">What are the possible risks and adverse effects of progestogen-only pills (POPs)?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a2486393-d1f2-481f-aa5f-1a44e4ecc0b6 --><!-- begin field 55f2e85a-b640-439e-9565-e90382fc22ac --><ul><li><strong>Menstrual irregularities </strong>—<strong> </strong>changes in bleeding patterns are common. For more<strong> </strong>information, see the section on <a class="topic-reference internal-reference" href="index.html#unscheduled-bleeding">unscheduled bleeding</a>.</li><li><strong>Breast tenderness </strong>— this is usually transient. However, if it is persistently troublesome, consider changing to <a class="topic-reference internal-reference" href="index.html#types-of-progestogen-only-pill">another progestogen-only pill</a> (POP), or to another contraceptive method. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a> for information on other contraceptive methods.</li><li><strong>Ovarian cysts</strong> — POP use is associated with around 30% higher risk of developing spontaneously reversible ovarian cysts.</li><li><strong>Ectopic pregnancy</strong> — there is a small increased risk of ectopic pregnancy in women using POPs (with the exception of desogestrel), but the absolute risk is lower than if not using contraception. Around 1 in 10 pregnancies that occur may be ectopic.</li><li><strong>Increased cancer risk </strong>— there is a possible increased risk of breast cancer with the use of POPs. However, this risk is very small compared with the overall risk of developing breast cancer, and 10 years after stopping the POP, the risk of developing breast cancer is the same as for women who have never used hormonal contraceptives.<ul><li>Compared with women who have never used the POP:<ul><li>In 10,000 women who use the POP for up to 5 years and stop by the age of 20 years, less than 1 additional case of breast cancer will be diagnosed up to 10 years afterwards.</li><li>In 10,000 women who use the POP for up to 5 years and stop by the age of 30 years, about 2–3 extra cases of breast cancer (in addition to 44 cases per 10,000 women in this age group that have never used oral contraceptives) will be diagnosed up to 10 years afterwards.</li><li>In 10,000 women who use the POP for up to 5 years and stop by the age of 40 years, about 10 extra cases of breast cancer (in addition to 160 cases per 10,000 women in this age group that have never used oral contraceptives) will be diagnosed up to 10 years afterwards.</li></ul></li><li>There is no evidence for any increased risk of other cancers and the POP may reduce the risk of endometrial cancer.</li></ul></li><li><strong>There is no evidence that the POP causes:</strong><ul><li>Depression and mood changes (although mood changes have been reported. Panic attacks have also been reported in women using desogestrel).</li><li>Headache.</li><li>Libido changes (however this is listed in the manufacturer's Summary of Product Characteristics).</li><li>Cardiovascular disease, including myocardial infarction, venous thromboembolism, and stroke.</li><li>Weight changes (although this has been reported in women using the POP in clinical trials).</li></ul></li></ul><p>[<a class="bibliography-reference internal-reference" href="../../references/index.html">BJCP, 2018</a>]</p><!-- end field 55f2e85a-b640-439e-9565-e90382fc22ac --><!-- end item a2486393-d1f2-481f-aa5f-1a44e4ecc0b6 --></div><section aria-labelledby="unscheduled-bleeding" class="ChapterBody-module--wrapper--2HCfk "><h4 id="unscheduled-bleeding">How should I manage unscheduled bleeding in a woman using a progestogen-only pill?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item fe6695d0-a664-4e56-ab00-a6ce007b4f53 --><!-- begin field 6779470e-f1d8-43e0-9545-a6ce008f52c6 --><ul><li><strong>Exclude and/or manage:</strong><ul><li>Situations which could compromise the effectiveness of progestogen-only pills (POPs) such as missed pills, drug interactions, and vomiting or diarrhoea.</li><li>Situations which could result in unscheduled bleeding, such as:<ul><li>Sexually transmitted infections (STIs) — as a minimum, test for <em>Chlamydia trachomatis. </em>The risk of STIs is increased if the woman is under 25 years, has a new sexual partner, or has had more than one sexual partner in the last year. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../chlamydia-uncomplicated-genital/index.html">Chlamydia - uncomplicated genital</a>.</li><li>Pregnancy — perform a pregnancy test.</li><li>Gynaecological conditions such as cervical cancer — if this is suspected, refer the woman using a suspected cancer pathway referral (for an appointment within 2 weeks). For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../gynaecological-cancers-recognition-referral/index.html">Gynaecological cancers - recognition and referral</a>.</li><li>Endometrial cancer — refer women aged 45 and older using a suspected cancer pathway referral (for an appointment within 2 weeks) if they have menstrual irregularities. Refer women younger than 45 years if they have risk factors for endometrial cancer and persistent, problematic bleeding after the first 3 months of use, or if they present with a change in bleeding pattern after at least 3 months of use. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../gynaecological-cancers-recognition-referral/index.html">Gynaecological cancers - recognition and referral</a>.</li></ul></li></ul></li><li><strong>Consider performing a speculum and pelvic examination:</strong><ul><li>For persistent bleeding beyond the first 3 months of use — unscheduled bleeding is common in the first 3 months of starting a new hormonal contraceptive method.</li><li>For new symptoms or a change in bleeding after at least 3 months of use.</li><li>If the woman has not participated in the NHS Cervical Screening Programme regularly. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../cervical-cancer-hpv/index.html">Cervical cancer and HPV</a>.</li><li>If requested by the woman.</li><li>If there are other symptoms such as pelvic pain, dyspareunia, or post-coital bleeding. </li></ul></li><li>If no other underlying cause of irregular bleeding is suspected, and speculum and pelvic examination is normal, the bleeding can be assumed to be caused by the POP. Providing the woman has no other symptoms:<ul><li>Reassure her that unscheduled bleeding is common in POP users.</li><li>Advise her that although bleeding may settle with time, there is no evidence to indicate which women may become amenorrhoeic, or which women may experience persistent irregular bleeding, or for how this will continue. As a general guide, over 12 months' of use, over a 3-month interval:<ul><li>5 in 10 women will be amenorrhoeic or have infrequent bleeding.</li><li>4 in 10 women will have 3–5 bleeding/spotting episodes (regular bleeding).</li><li>1 in 10 women will have 6 or more bleeding/spotting episodes (frequent bleeding).</li><li>2 in 10 women will have bleeding/spotting episodes lasting more than 14 days (prolonged bleeding).</li></ul></li><li>If the bleeding is unacceptable to the woman, consider changing to:<ul><li>A different POP, although there is no evidence that changing the progestogen type or dose improves bleeding.</li><li>A different type of contraceptive method. See the CKS topic on Contraception - assessment for information on other contraceptive methods.</li></ul></li></ul></li></ul><!-- end field 6779470e-f1d8-43e0-9545-a6ce008f52c6 --><!-- end item fe6695d0-a664-4e56-ab00-a6ce007b4f53 --></div></section><section aria-labelledby="basis-for-recommendation-ada" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-ada">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ada74ae4-51c7-4007-ac5f-3b9bd19825f0 --><!-- begin field 961e4e50-83f4-4ddd-a9b1-52c6e62c61c9 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines, <em>Progestogen-only pills</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015a</a>], <em>Problematic bleeding with hormonal contraception </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015c</a>], the National Institute for Health and Care Excellence (NICE) guideline <em>Suspected cancer: recognition and </em><em>referral</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>], and the manufacturer's Summary of Product Characteristics [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2015a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016a</a>].</p><h5>Endometrial cancer</h5><ul><li>NICE advises considering using a suspected cancer pathway referral (for an appointment within 2 weeks) for women aged under 55 years with post-menopausal bleeding. However, the FSRH advises that an endometrial biopsy should be considered in women aged 45 years or over and in women under 45 years with risk factors for endometrial cancer who have persistent problematic bleeding after the first 3 months of using a method, or who present with a change in bleeding pattern [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015c</a>].</li></ul><!-- end field 961e4e50-83f4-4ddd-a9b1-52c6e62c61c9 --><!-- end item ada74ae4-51c7-4007-ac5f-3b9bd19825f0 --></div></section></section><section aria-labelledby="efficacy" class="ChapterBody-module--wrapper--2HCfk "><h3 id="efficacy">How effective are progestogen-only pills (POPs) at preventing pregnancy?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 28710306-aa7b-4f7c-97d0-b310e87385e1 --><!-- begin field dd068574-5eb8-4bec-808d-05fadfc5b4c7 --><ul><li>For a comparison of the efficacy of progestogen-only pills (POPs) with other methods of contraception, see the section on <a class="topic-reference external-reference" href="../../../contraception-assessment/background-information/comparative-effectiveness-of-contraceptive-methods/index.html">Comparative efficacy</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a>.<ul><li>When used perfectly (consistently and correctly), 0.3% of women will conceive within the first year of use due to method failure.</li><li>When used typically, 9% of women will conceive within the first year of use due to method failure or user failure.</li></ul></li></ul><!-- end field dd068574-5eb8-4bec-808d-05fadfc5b4c7 --><!-- end item 28710306-aa7b-4f7c-97d0-b310e87385e1 --></div><section aria-labelledby="basis-for-recommendation-864" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-864">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8645f5e5-e957-4e36-bd7b-3e68b26ae8f0 --><!-- begin field bfbf136a-a87b-4f14-a57c-25b1a7499749 --><p>This information is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only pills </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015a</a>], and on expert opinion in the medical textbook <em>Contraceptive technology</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Hatcher, 2011</a>].</p><!-- end field bfbf136a-a87b-4f14-a57c-25b1a7499749 --><!-- end item 8645f5e5-e957-4e36-bd7b-3e68b26ae8f0 --></div></section></section><section aria-labelledby="drug-interactions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="drug-interactions">What are the key drug interactions for progestogen-only pills?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item cd0170e6-81ed-4cd9-9642-d44a35e90d26 --><!-- begin field 80079242-b4d1-4d85-a1df-c3ada6bc3527 --><h4>Liver enzyme-inducing drugs</h4><ul><li>Advise the woman that liver enzyme-inducing drugs may reduce the efficacy of progestogen–only pills (POPs). Examples of liver enzyme-inducing drugs are:<ul><li>Antibiotics — rifampicin and rifabutin are very potent liver enzyme inducers.</li><li>Antiepileptic drugs such as carbamazepine, oxcarbazepine, phenytoin, barbiturates, primidone, and topiramate.<ul><li>Topiramate is associated with a risk of fetal malformations and can impair the effectiveness of hormonal contraceptives. Before initiating topiramate in a woman of childbearing potential, pregnancy testing should be performed. The patient should be fully informed of the risks related to the use of topiramate during pregnancy. Ensure that women and girls of childbearing potential are advised that they should be using a highly effective method of contraception [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017</a>]. </li></ul></li><li>Antiretrovirals such as ritonavir, ritonavir-boosted protease inhibitors, efavirenz, and nevirapine.</li><li>St John's wort — advise women taking the POP not to take herbal products containing St John’s wort.</li></ul></li><li><strong>If a woman is on short-term treatment (2 months or less) with a liver enzyme-inducing drug:</strong><ul><li>Advise her to stop the POP and change to an alternative contraceptive method unaffected by liver enzyme-inducing drugs.<ul><li>For example having a one-off progestogen-only injection to cover the short-term treatment and for 28 days after.</li></ul></li><li>If this is not acceptable or possible:<ul><li>Continue the POP. </li><li>Advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) while taking, and for 28 days after stopping, the liver enzyme-inducing drug.</li></ul></li><li>Consider the need for emergency contraception (EC) if unprotected sexual intercourse has taken place while the efficacy of the POP may have been reduced, for example if the woman has already started treatment with a liver enzyme-inducing drug. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-emergency/index.html">Contraception - emergency</a>.</li></ul></li></ul><ul><li><strong>If a woman is on long-term treatment (more than 2 months) with a liver enzyme-inducing drug:</strong><ul><li>Advise her to change to an alternative contraceptive method unaffected by liver enzyme-inducing drugs (such as barrier methods or the progestogen-only injectable). </li><li>Do not increase the dose of the POP.</li><li>Consider the need for EC if sexual intercourse has taken place while the efficacy of the POP may have been reduced, for example if the woman has already started treatment with a liver enzyme-inducing drug. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-emergency/index.html">Contraception - emergency</a>.</li></ul></li></ul><h4>Griseofulvin</h4><ul><li><strong>Griseofulvin may reduce the contraceptive effect of POPs </strong>— advise the woman to change to an alternative method of contraception unaffected by griseofulvin. </li></ul><h4>Lamotrigine</h4><ul><li><strong>Lamotrigine increases plasma levels of progestogen </strong>— monitor for adverse effects of POP.</li></ul><h4>Ulipristal acetate (Esmya®)</h4><ul><li>Ulipristal acetate 5 mg (Esmya®) is licensed for the pre-operative treatment of moderate to severe symptoms of uterine fibroids. The dose (5 mg daily) is lower than that used for emergency contraception (30 mg as a one-off dose). The manufacturers of Esmya® advise avoiding concomitant use of POPs as they may reduce the efficacy of ulipristal.</li></ul><!-- end field 80079242-b4d1-4d85-a1df-c3ada6bc3527 --><!-- end item cd0170e6-81ed-4cd9-9642-d44a35e90d26 --></div><section aria-labelledby="basis-for-recommendation-4f3" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-4f3">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4f369a24-bfeb-47b4-9ca8-a9e32572d74f --><!-- begin field ce90acd6-6a40-497a-8b5e-51a286c4dad8 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines, <em>Progestogen-only pills</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015a</a>], <em>Drug interactions with hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2012</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2017a</a>], and the manufacturer's Summaries of Product Characteristics [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016b</a>].</p><!-- end field ce90acd6-6a40-497a-8b5e-51a286c4dad8 --><!-- end item 4f369a24-bfeb-47b4-9ca8-a9e32572d74f --></div></section></section><section aria-labelledby="follow-up" class="ChapterBody-module--wrapper--2HCfk "><h3 id="follow-up">What follow up should I consider for a woman using a progestogen-only pill (POP)?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1694dec5-2f66-4fd8-830a-e59f51e6b747 --><!-- begin field c0b5628b-f3c4-4488-95b0-809802cfa64e --><ul><li>Arrange follow up 10–12 weeks after the first prescription of a progestogen-only pill (POP) and then at least every 12 months thereafter, provided there are no troublesome adverse effects.</li><li>At the follow up visit:<ul><li>Check the woman's blood pressure and body mass index.</li><li>Assess the woman for any new risk factors that may mean this method is no longer suitable. For more information, see the topic on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a>. </li><li>Ask about any <a class="topic-reference internal-reference" href="index.html#risks-adverse-effects">adverse effects</a>. </li><li>Check that the woman is taking the POP correctly and consistently.</li><li>Check her knowledge of what to do if a pill is <a class="topic-reference internal-reference" href="index.html#missed-pill">missed</a>.</li><li>Remind her about possible <a class="topic-reference internal-reference" href="index.html#drug-interactions">drug interactions</a>.</li></ul></li><li>Offer verbal and/or written advice on long-acting reversible contraception (copper intrauterine device, levonorgestrel intrauterine system, progestogen-only injectables, progestogen-only implant, and the combined hormonal vaginal ring). For more information, see the CKS topics on <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a> and <a class="topic-reference external-reference" href="../../../contraception-combined-hormonal-methods/index.html">Contraception - combined hormonal methods</a>.</li></ul><!-- end field c0b5628b-f3c4-4488-95b0-809802cfa64e --><!-- end item 1694dec5-2f66-4fd8-830a-e59f51e6b747 --></div><section aria-labelledby="duration-of-use" class="ChapterBody-module--wrapper--2HCfk "><h4 id="duration-of-use">How long should the progestogen-only pill (POP) be used for?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 28bf27ea-69c6-4c37-b41e-a6ce0093f1ca --><!-- begin field c43f2795-aecd-4f85-bc90-a6ce0093f366 --><ul><li><strong>If the woman is not amenorrhoeic,</strong> continue the progestogen-only pill (POP) over 55 years of age until she has been amenorrhoeic for 1 year. </li><li><strong>If the woman is amenorrhoeic</strong>, consider one of the following options:<ul><li>For a woman over the age of 50 years, check serum follicle stimulating hormone (FSH) levels on two occasions, with an interval of 6 weeks between tests. If both FSH levels are more than 30 IU/L, stop the POP after a further year.</li><li>Continue the POP until the age of 55 years if required and requested.</li></ul></li></ul><!-- end field c43f2795-aecd-4f85-bc90-a6ce0093f366 --><!-- end item 28bf27ea-69c6-4c37-b41e-a6ce0093f1ca --></div></section><section aria-labelledby="basis-for-recommendation-0e7" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-0e7">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0e709fb4-2310-4fa6-a465-35e11dbbb42d --><!-- begin field 3806d4aa-30b3-4f1e-9fda-50af3683fa2d --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only pills</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015a</a>], <em>Contraception for women aged over 40 years</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2010b</a>] and expert opinion in a medical textbook, <em>Contraception today</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Guillebaud, 2016</a>].</p><!-- end field 3806d4aa-30b3-4f1e-9fda-50af3683fa2d --><!-- end item 0e709fb4-2310-4fa6-a465-35e11dbbb42d --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/contraception-progestogen-only-methods/management/progestogen-only-pill/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>